Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- ASKA to Launch Blopress AGs on Sept 12
August 6, 2014
- Hisamitsu to Dissolve US JV with Novartis Pharmaceuticals
August 6, 2014
- Eli Lilly Japan Files NDA for GLP-1 Receptor Agonist Dulaglutide
August 6, 2014
- Eisai Ends Development of Diabetic Complication Treatment
August 5, 2014
- Development of Antibody Drugs Accelerating in the Field of Asthma; First New Option Could Be Available as Early as 2016
August 5, 2014
- Otsuka, UCB Japan File E Keppra Injectable for Monotherapy
August 5, 2014
- Celgene Files NDA for Hematopoietic Malignancy Treatment Pomalidomide in Japan
August 5, 2014
- Kyowa Kirin Files NDA for Antithrombin Preparation KW-3357
August 5, 2014
- Asahi Kasei Pharma Files NDA for Xiaflex for Treatment of Dupuytren’s Contracture
August 4, 2014
- Taiho to Terminate Multinational PIII Study of Angiogenesis Inhibitor Orantinib for Hepatocellular Carcinoma
August 4, 2014
- Daiichi Sankyo to Transfer Akita Plant to Alfresa Pharma
August 4, 2014
- Kyowa Kirin, AstraZeneca Hook Up in Immuno-Oncology Clinical Study
August 1, 2014
- Kyowa Kirin Taking Nesp Issue Seriously from Ethical Standpoint: Pres.
August 1, 2014
- Anticancer Agent Lenvatinib Granted EMA Accelerated Review: Eisai
August 1, 2014
- Kyowa Kirin to Outsource Sales of Recombinant Human Antithrombin Preparation to JB
August 1, 2014
- Takara Bio to Buy Swedish Stem Cell Company
July 31, 2014
- Kyowa Kirin’s Half-Year Pharma Operating Profit Tumbles 41% on Price Cuts
July 31, 2014
- Nissan Chemical Files Livalo Patent Suit against Sawai in US
July 31, 2014
- Sanofi Files NDA for HOE901-U300, Successor Drug to Lantus, in Japan
July 31, 2014
- LSI Medience, Kyushu TLO Jointly Set Up KPSL, New Business Entity in Clinical Laboratory Test Field
July 31, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…